Montelukast Aurobindo Pharma Italia (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from triggering bronchoconstriction, airway edema, and inflammatory cell recruitment. This results in reduced airway narrowing and inflammation.

The prescribed dose of Montelukast is determined by the treating clinician based on the patient’s age, weight, and specific condition. Typical regimens involve once‑daily oral administration, but exact dosing must be set by a qualified healthcare professional.

Safety data for Montelukast in pregnancy are limited, and the pregnancy category is listed as unknown. It should be used only if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should discuss possible exposure with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast targets leukotriene‑mediated inflammation, whereas inhaled corticosteroids act broadly on airway inflammation. Montelukast is often used as an add‑on therapy for patients whose asthma is not fully controlled with inhaled steroids, but it is not a substitute for rescue bronchodilators.

Store the tablets at ambient temperature below 25 °C, in the original container, and protect them from moisture and direct sunlight. Keep out of reach of children and do not use after the expiry date.

Montelukast is taken orally as a tablet, swallowed whole with water. It may be taken with or without food, and the same time each day is recommended to maintain steady plasma levels.

Serious but rare risks include angioedema, severe skin reactions such as Stevens‑Johnson syndrome, eosinophilic granulomatosis with polyangiitis, hepatic injury, anaphylaxis, and neuropsychiatric events like mood changes or suicidal thoughts. Prompt medical attention is required if any of these occur.

Montelukast should be avoided in individuals with known hypersensitivity to montelukast or any of its excipients. Caution is advised for patients with severe liver disease, and it is not intended for the acute relief of bronchospasm during an asthma attack.